Shared on 01 May 25
Fair value Increased 39%Advanced Wound Care Demand Will Unlock Global Opportunities
Shared on 24 Apr 25
Fair value Decreased 24%FDA Approval And Phase III Trial Will Expand Wound Care
AnalystConsensusTarget has increased shares outstanding growth rate from 0.1% to 0.2%.
Shared on 17 Apr 25
FDA Approval And Phase III Trial Will Expand Wound Care
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Decreased 5.63%FDA Approval And Phase III Trial Will Expand Wound Care
AnalystConsensusTarget has decreased revenue growth from 30.0% to 25.9% and decreased shares outstanding growth rate from 0.2% to 0.1%.